



# Bladder17<sup>®</sup>

## Non-Invasive Testing for Confident Bladder Cancer Management

Bladder cancer requires ongoing monitoring, yet traditional methods can be invasive, costly, and uncomfortable for patients. Bladder17<sup>®</sup> offers a non-invasive urine-based solution designed to support early detection and recurrence monitoring. Helping clinicians make faster, more informed decisions with greater patient comfort.

### Why Bladder17<sup>®</sup>

- **Simple, non-invasive urine collection**
- **99% Negative Predictive Value (NPV) supports confident rule-out of bladder cancer\***
- Supports recurrence monitoring without routine invasive procedures
- Designed for surveillance and high-risk patient populations

### Key Benefits

99% Negative Predictive Value\*

Non-invasive urine-based testing

Detects both low- and high-grade bladder cancer

Reimbursable under applicable CPT codes

Designed for At-Risk Populations: Smokers, increasing age, occupational exposure, cancer treatment

### Why EmeritusDX?

- Advanced urine-based molecular testing designed to support confident bladder cancer management
- Helps support recurrence monitoring without routine invasive procedures
- Designed for high-risk and surveillance patient populations
- CAP-accredited
- CLIA-certified

### Clinical Risk Stratification Support\*\*

#### Lower-Risk Profile

Negative/Atypical Cytology + Negative Bladder17<sup>®</sup> = No to low risk of bladder cancer

#### Elevated-Risk Findings

Elevated Bladder17<sup>®</sup> Expression: Standard diagnostic workout is recommended

\*Guo L, Cid A, Cucci J, et al. Acu-URO17 is a highly sensitive and specific bladder cancer biomarker. BJUI Compass. 2024.

\*\*Babu et al. 2019. Modern Pathology. Vasdev et al. 2020. Babu et al 2021

